Investment Thesis
Summit Therapeutics is a pre-revenue pharmaceutical development company with -$1.1B operating losses and -$122M annual operating cash burn. With only $106.5M in cash reserves, the company faces critical runway pressure (less than 12 months) and is entirely dependent on successful drug development or capital raises for survival. While the balance sheet shows $545.9M in equity with minimal debt, the absence of any revenue generation and unsustainable cash burn trajectory present unacceptable fundamental risks.
Strengths
- Strong balance sheet with $545.9M stockholders' equity against only $101.9M total liabilities
- Excellent liquidity position (7.41x current ratio) with zero material long-term debt
- Minimal capital expenditure requirements ($245K) suggesting efficient asset-light R&D model
Risks
- Zero revenue with no approved commercial products, indicating pre-commercialization development stage
- Critical cash runway: $106.5M in reserves against $122M annual operating burn rate (less than 1 year)
- Massive operating losses (-$1.1B) driven by R&D spend with no clear path to profitability
- Complete execution dependence on unproven drug pipeline success and regulatory approvals
- No insider buying activity (0 Form 4 filings in 90 days) suggesting lack of internal confidence
Key Metrics to Watch
- Monthly operating cash burn rate and runway extension through capital raises or revenue
- Clinical trial progress, regulatory milestones, and FDA approval timeline for pipeline candidates
- Cash balance trend and timing of first commercial revenue recognition
Financial Metrics
Revenue
0.0
Net Income
-189.4M
EPS (Diluted)
$-0.24
Free Cash Flow
-122.5M
Total Assets
647.9M
Cash
106.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-34.7%
ROA
-29.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.41x
Quick Ratio
7.41x
Debt/Equity
0.00x
Debt/Assets
15.7%
Interest Coverage
-124.42x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:08:02.112542 |
Data as of: 2026-03-31 |
Powered by Claude AI